Goldman Sachs
BIOSW

Goldman Sachs’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

Goldman Sachs’s Portfolio BIOSW Stock Details BIOSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-412,547
Closed -$23.1K – 5993
2023
Q3 		$23.1K Hold
412,547
– – ﹤0.01% 5343
2023
Q2 		$53.1K Hold
412,547
– – ﹤0.01% 5458
2023
Q1 		$33K Hold
412,547
– – ﹤0.01% 5612
2022
Q4 		$4.99K Hold
412,547
– – ﹤0.01% 5813
2022
Q3 		$36K Hold
412,547
– – ﹤0.01% 5838
2022
Q2 		$58K Hold
412,547
– – ﹤0.01% 5999
2022
Q1 		$95K Buy
+412,547
New +$107K ﹤0.01% 6122

Goldman Sachs's BIOSW Position: Q4 2023 in Review

Goldman Sachs sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q4 2023, closing a stake of 412,547 shares — an estimated $23.1K sold.

Goldman Sachs first reported a position in BIOSW in Q1 2022 and held it in 7 quarters. The position peaked at $95K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOSW as of Q4 2023.

  • Goldman Sachs reported no remaining BioPlus Acquisition Corp. Warrants position as of Q4 2023 after selling out during the quarter.
  • Goldman Sachs sold 412,547 BioPlus Acquisition Corp. Warrants shares in Q4 2023, an estimated $23.1K.
  • Goldman Sachs first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 7 quarters.
  • Goldman Sachs's BioPlus Acquisition Corp. Warrants position peaked at $95K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q4 2023.

Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.